---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-079500"
form_type: "8-K"
ticker: "ACRV"
cik: "0001781174"
company_name: "Acrivon Therapeutics, Inc."
filed_at: "2026-02-27T23:59:59+00:00"
generated_at: "2026-05-15T23:09:56.589225+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "low"
source: SEC EDGAR
---

# ACR-368 interim data from registrational-intent arms presented at ESGO for endometrial cancer serous subtype

## Summary
- Interim data from ACR-368 Phase 2b registrational-intent trial presented at ESGO Congress on February 27, 2026.
- Data focused on endometrial cancer, particularly the serous sub-type.
- KOL panel discussed potential of ACR-368 to address unmet need in this patient population.
- Company-sponsored webcast with on-site and virtual participation.

## SEC filing metadata
- accession: 0001193125-26-079500
- form_type: 8-K
- ticker: ACRV
- cik: 0001781174
- company_name: Acrivon Therapeutics, Inc.
- filed_at: 2026-02-27T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: low
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1781174/000119312526079500/0001193125-26-079500-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1781174/000119312526079500/d116670d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-079500
- JSON: https://secwatch.observer/filing/0001193125-26-079500.json
- Plain text: https://secwatch.observer/filing/0001193125-26-079500.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.